The newly approved autoinjector provides an alternative to the prefilled syringe for daily self-administration.
The FDA has granted over-the-counter approval to Brytly (apraclonidine ophthalmic solution 0.125%) for the symptomatic relief of eye redness due to minor irritation in individuals aged 12 years and ...
Dr Hamzavi discussed how to navigate conversations with patients with HS regarding common misconceptions, expectations with ...
Real-world data from Fall Clinical 2026 reveal widespread treatment dissatisfaction, anxiety, and steroid hesitancy among ...
Subcutaneous interleukin-6 receptor antagonist approved for adult patients with active or inactive thyroid eye disease regardless of disease duration.
Experts at the 2026 Fall Clinical Dermatology Conference review landmark drug approvals, emerging pipelines, and updated ...
The expansion marks the first therapy approved for patients with BCG-unresponsive non-muscle-invasive bladder cancer presenting with papillary-only disease.
Real-world GPP data show low uptake of targeted IL-36 inhibitors and persistent reliance on corticosteroids and non-GPP ...
Dr Ablon discusses important key points providers should keep in mind during their evaluations of patients seeking aesthetic ...
Risk for ischemic stroke, myocardial infarction were increased with prolonged use with doses >1 mg/day for more than one year ...
Immediate symptomatic relief and long-term neuroimmunomodulation seen with acupressure combined with pharmacotherapy ...
A nationwide voluntary recall has been issued for 22 lots of Argatroban Injection due to the presence of multi-material particulate contamination, posing potential life-threatening risks.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results